| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
AS602801 (also known as Bentamapimod and PGL5001) is a novel, potent and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with IC50 values of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively. It functions as a JNK inhibitor and could decrease the induced endometriosis in the baboon without having a significant impact on the length of the cycle, the levels of serum reproductive hormones, or any significant adverse effects on the endocrine system. Preglem's AS602801 Phase 2 Trial (NCT01630252) is now complete.
| Targets |
JNK1 (IC50 = 80 nM); JNK2 (IC50 = 90 nM); JNK3 (IC50 = 230 nM)
|
|---|---|
| ln Vitro |
In vitro, AS602801 demonstrates cytotoxicity against both serum-cultured non-stem cancer cells and cancer stem cells derived from human pancreatic cancer, non-small cell lung cancer, ovarian cancer, and glioblastoma at concentrations that do not impair the viability of healthy human fibroblasts. Additionally, AS602801 prevents cancer stem cells that have survived treatment from renewing themselves and starting tumors[2].
|
| ln Vivo |
Systemic administration of AS602801 at a dose and schedule that did not negatively impact the health of the tumor-bearing mice reduced the number of cancer stem cells in established xenograft tumors[2].
|
| Enzyme Assay |
AS602801 (also known as Bentamapimod and PGL5001) is a novel, potent and ATP-competitive JNK (c-Jun N-terminal Kinase) inhibitor with IC50 values of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively. It functions as a JNK inhibitor and can lessen the surface area and volume of induced endometriosis in baboons without having a significant impact on cycle length or serum levels of reproductive hormones or having any significant adverse effects on the endocrine system.
|
| Cell Assay |
Human IMR90 normal fibroblasts and human cancer cells PANC-1, A2780, and A549 are subjected to a 3-day treatment period with or without bentamapimod (AS 602801) at the indicated concentrations (2.5, 5, or 7.5 μM). Using trypan blue as a vital dye, researchers were able to count the number of viable cells (left panels) and the percentage of dead cells (right panels)[2].
|
| Animal Protocol |
Mice: The silastic capsule containing 8 μg of estradiol is implanted subcutaneously into the 5-week-old athymic (ncr/nude) ovariectomized mice after isoflurane anesthesia. Twenty-four hours later, mice were injected subcutaneously or intraperitoneally with a phosphate-buffered saline (PBS) suspension containing 8 to 10 fragments of human endometrial tissue per mouse (biopsies taken from volunteers or patients) on the ventral midline just below the umbilicus. Tissue fragments are cultured as organs for 24 hours prior to injection while being treated with 1 nM estradiol, PR, or MPA. Bentamapimod (AS 602801) is first administered orally 10 to 12 days after tissue injection. MPA is administered twice weekly by tuberculin syringe injections (200 mg/kg) along the right flank, and progesterone is administered via a slow-release silastic capsule containing 25 μg PR. Gavage administration of bentamapimod (AS 602801) is carried out for 30 days at doses of 10 mg/kg and 30 mg/kg/animal. In order to directly examine the size and number of lesions, mice are once more given general anesthesia and sacrificed by cervical dislocation after the course of treatment is complete. In order to facilitate further analysis, excised lesions from uteri are weighed and measured[3].
|
| References |
|
| Molecular Formula |
C25H23N5O2S
|
|
|---|---|---|
| Molecular Weight |
457.55
|
|
| Exact Mass |
457.16
|
|
| Elemental Analysis |
C, 65.63; H, 5.07; N, 15.31; O, 6.99; S, 7.01
|
|
| CAS # |
848344-36-5
|
|
| Related CAS # |
|
|
| Appearance |
Solid powder
|
|
| SMILES |
C1COCCN1CC2=CC=C(C=C2)COC3=NC=CC(=N3)C(C#N)C4=NC5=CC=CC=C5S4
|
|
| InChi Key |
XCPPIJCBCWUBNT-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C25H23N5O2S/c26-15-20(24-28-22-3-1-2-4-23(22)33-24)21-9-10-27-25(29-21)32-17-19-7-5-18(6-8-19)16-30-11-13-31-14-12-30/h1-10,20H,11-14,16-17H2
|
|
| Chemical Name |
2-(1,3-benzothiazol-2-yl)-2-[2-[[4-(morpholin-4-ylmethyl)phenyl]methoxy]pyrimidin-4-yl]acetonitrile
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (1.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 + to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1856 mL | 10.9278 mL | 21.8555 mL | |
| 5 mM | 0.4371 mL | 2.1856 mL | 4.3711 mL | |
| 10 mM | 0.2186 mL | 1.0928 mL | 2.1856 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01630252 | Completed | Drug: PGL5001 Drug: Placebo |
Endometriosis | PregLem SA | June 2012 | Phase 2 |
Bentamapimod (AS-01) causes reduction in the expression of genes previously associated with endometriosis in endometriotic-like lesions established with biopsies from patients with disease.Reprod Sci.2016 Jan;23(1):11-23. |
|---|
|
Bentamapimod at both 30 mg/kg twice daily (BID) and 60 mg/kg BID causes regression of surgically induced autologous endometriotic-like foci in rats.
Cytotoxic activity of natural killer (NK) cells from splenocytes. Splenocytes isolated from endometriotic rat after their treatment were subjected to lytic activity of the target cells as described in the Methods section.Reprod Sci.2016 Jan;23(1):11-23. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
